26 Feb Ilya Pharma AB – Revolutionising wound care
Ilya Pharma is developing the next-generation biological drugs for treating wounds in skin and mucosa. The cost effective innovation uses lactic acid bacteria as small bioreactors to produce and deliver human effector proteins on site. This new technology offers a more efficient treatment for healing both acute and chronic wounds.
The unmet clinical need targeted by Ilya Pharma is healing both acute and chronic wounds, especially problematic for people with diabetes. Indications in the gastrointestinal tract such as irritable bowel disease are also being explored.
Ilya Pharma, founded in 2016, is a spin-out pharmaceutical company with its medical innovation stemming from many years of scientific reasearch at Uppsala University and the Swedish University of Agriculture.